AAD 2024: Upadacitinib Reduces Atopic Dermatitis-Related Nighttime Itch, Sleep Disturbances
Treatment with 15-mg or 30-mg doses improved length of time patients experienced symptom improvements
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.